First Allied Advisory Services Inc. Lowers Holdings in Amgen, Inc. (AMGN)
First Allied Advisory Services Inc. decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.4% during the fourth quarter, HoldingsChannel reports. The firm owned 37,445 shares of the medical research company’s stock after selling 1,703 shares during the period. First Allied Advisory Services Inc.’s holdings in Amgen were worth $7,334,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Commonwealth Bank of Australia increased its holdings in shares of Amgen by 19.7% in the fourth quarter. Commonwealth Bank of Australia now owns 66,961 shares of the medical research company’s stock worth $13,027,000 after buying an additional 11,040 shares during the period. UNIVEST FINANCIAL Corp increased its holdings in shares of Amgen by 1.5% in the fourth quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock worth $4,583,000 after buying an additional 355 shares during the period. Duality Advisers LP purchased a new position in shares of Amgen in the fourth quarter worth about $3,983,000. Pensionfund DSM Netherlands purchased a new position in shares of Amgen in the fourth quarter worth about $3,738,000. Finally, Congress Asset Management Co. MA increased its holdings in shares of Amgen by 0.8% in the fourth quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock worth $7,909,000 after buying an additional 311 shares during the period. Institutional investors and hedge funds own 79.18% of the company’s stock.
NASDAQ AMGN opened at $176.36 on Tuesday. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The stock has a market capitalization of $108.63 billion, a P/E ratio of 12.25, a price-to-earnings-growth ratio of 2.17 and a beta of 1.21. Amgen, Inc. has a 1 year low of $165.22 and a 1 year high of $210.19.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.29%. Amgen’s payout ratio is 40.28%.
Several research analysts have recently commented on AMGN shares. BMO Capital Markets started coverage on Amgen in a report on Thursday, March 14th. They issued an “outperform” rating and a $228.00 price objective on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $190.00 price objective on shares of Amgen in a report on Wednesday, January 30th. Leerink Swann decreased their price objective on Amgen from $200.00 to $192.00 and set a “market perform” rating on the stock in a report on Wednesday, January 30th. Oppenheimer set a $224.00 price objective on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Finally, Citigroup raised their target price on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research note on Friday, January 4th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. Amgen presently has a consensus rating of “Hold” and a consensus price target of $209.11.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the sale, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 6,000 shares of company stock worth $1,144,120. Insiders own 0.27% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Technical Analysis
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.